You are here: Industry Insights > gene therapy

News List

Neurogene raises funds to support gene therapy development pharmaceutical-technology
February 15, 2019
Neurogene has secured funding during a Series A financing round to advance the development of its gene therapy candidates intended for the treatment of various neurological diseases....
Gene therapy biotech shares sink on inconclusive trial results pharmaphorum
February 14, 2019
Shares in two US gene therapy biotechs have fallen after two cutting-edge treatments failed to produce convincing results in early clinical trials.
Rocket Pharmaceuticals Announces Clearance of IND for RP-A501 Gene Therapy for Danon Disease firstwordpharma
January 23, 2019
In parallel with the Phase 1 clinical trial, the Company plans to publish a comprehensive literature review of Danon cases and conduct a retrospective chart review. In addition, the Company will initiate a prospective natural history study with enrollment
Rocket Pharmaceuticals Announces Clearance of IND for RP-A501 Gene Therapy for Danon Disease firstwordpharma
January 23, 2019
In parallel with the Phase 1 clinical trial, the Company plans to publish a comprehensive literature review of Danon cases and conduct a retrospective chart review. In addition, the Company will initiate a prospective natural history study with enrollment
Gene therapy promotes nerve regeneration firstwordpharma
January 21, 2019
Researchers from the Netherlands Institute for Neuroscience (NIN) and the Leiden University Medical Center (LUMC) have shown that treatment using gene therapy leads to a faster recovery after nerve damage.
Gene therapy promotes nerve regeneration firstwordpharma
January 21, 2019
Researchers from the Netherlands Institute for Neuroscience (NIN) and the Leiden University Medical Center (LUMC) have shown that treatment using gene therapy leads to a faster recovery after nerve damage.
Mundipharma to Bring World's First Gene Therapy for Osteoarthritis to Nine More Countries in APAC firstwordpharma
January 17, 2019
According to the World Health Organisation, osteoarthritis is the single most common cause of disability in older people with an estimated 10%-15% of all people over 60 suffering from it. Currently, its prevalence is increasing.
Ex-Roche, Novartis, AstraZeneca leaders appointed to biotech roles pharmaphorum
January 17, 2019
Three more big pharma R&D names have made the jump to biotech as Voyager Therapeutics, ImmunSYS and Immunocore announce they have appointed former execs from Roche, Novartis and AstraZeneca.
FDA announces new policies for cell and gene therapies pharmaceutical-technology
January 17, 2019
Despite most of the US Food and Drug Administration’s (FDA) responsibilities grinding to a halt as a result of the US Government shut down ....
Lilly’s CEO looks to M&A, but not for CAR-T or gene therapies pharmaphorum
January 15, 2019
Eli Lilly’s CEO David Ricks could sign more deals to strengthen its pipeline of cancer drugs, but is leaving gene cell-based CAR-T oncology drugs and rare disease gene therapies for others to develop......

Previous page 1 2 3 4 5 6 7 8 9 10 ... 20 21 Next page